Clinical trial
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
NCT00181688 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00181688 |
|---|---|
| Title | Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer |
| Official title | A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Carcinoma, Tubal Carcinoma |
| Intervention type | Drug |
| Interventions | Iressa (ZD1839), Arimidex (Anastrozole) |
| Enrollment | 35 |
| Start date | Oct 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 5, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: